Belite Bio Marks Enrollment Completion in the PHOENIX Trial
Belite Bio, a clinical-stage biopharmaceutical company dedicated to developing innovative treatments for degenerative retinal diseases, is thrilled to announce the successful completion of enrollment in its pivotal global Phase 3 PHOENIX trial. This groundbreaking study examines Tinlarebant, an oral medication aimed at slowing the progression of geographic atrophy (GA) associated with dry age-related macular degeneration (AMD).
With 500 subjects enrolled from diverse regions, including the United States, the United Kingdom, France, Czech Republic, Switzerland, China, Taiwan, and Australia, the trial has drawn notable global interest. The diverse participant base underscores the pressing need for effective treatment options and highlights the significance of the trial in addressing this unmet medical need.
What Is the PHOENIX Trial?
The PHOENIX trial is a comprehensive 24-month study designed to evaluate the safety and effectiveness of Tinlarebant. Dr. Tom Lin, Chairman and CEO of Belite Bio, emphasized the milestone's importance, stating, "Completing enrollment in the PHOENIX trial brings us closer to assessing Tinlarebant's potential to mitigate atrophic lesion growth in dry AMD, providing hope for those impacted by this debilitating condition."
Dr. Hendrik Scholl, Chief Medical Officer, expressed enthusiasm regarding the global engagement in the trial, remarking, "The strong enrollment figures reflect the high interest in our investigational therapy, particularly the appeal of a daily oral tablet compared to more invasive treatment methods." This innovative approach could represent a significant shift in how geographic atrophy is managed, offering a more patient-friendly treatment option.
Understanding Geographic Atrophy and Its Impact
Geographic atrophy is recognized as a severe stage of dry AMD and is a leading cause of vision loss, particularly among older adults. It manifests through the growth of lesions in the retina, leading to reduced vision and difficulties in performing daily activities such as reading and driving. With currently no approved oral treatments available for GA, the necessity for Tinlarebant, if successful, could be monumental.
The ongoing PHOENIX trial aims to assess the efficacy of Tinlarebant in curbing the growth of these damaging lesions, a crucial indicator of disease progression. As the trial progresses, researchers and participants alike remain hopeful for positive outcomes that can dramatically improve the quality of life for those living with GA.
About Tinlarebant
Tinlarebant is positioned as an oral therapeutic specifically designed to intervene early in the course of retinal diseases such as GA and Stargardt disease type 1 (STGD1). With no FDA-approved therapies available for these conditions, the potential for Tinlarebant to fill this gap is substantial. Its development has already received recognition, including Fast Track Designation and Breakthrough Therapy Designation in the United States, in addition to Orphan Drug Designation across multiple regions.
About Belite Bio
Belite Bio is committed to revolutionizing the treatment landscape for degenerative retinal diseases, continuously striving to develop novel therapeutics that meet significant unmet medical needs. Alongside Tinlarebant, the company is evaluating other promising candidates aimed at various retinal and metabolic diseases. As the Phase 3 PHOENIX trial unfolds, anticipation is building for interim results that could pave the way for crucial advancements in the management of geographic atrophy.
Frequently Asked Questions
What is the PHOENIX trial?
The PHOENIX trial is a pivotal Phase 3 study assessing the safety and efficacy of Tinlarebant in patients with geographic atrophy associated with dry AMD.
How many participants are enrolled in the trial?
500 subjects have been enrolled from various countries worldwide, highlighting the global interest in this treatment.
What condition does Tinlarebant target?
Tinlarebant is aimed at treating geographic atrophy, a severe form of dry age-related macular degeneration that leads to vision loss.
What makes Tinlarebant unique?
Tinlarebant is an orally administered therapy that offers a potential non-invasive treatment option for geographic atrophy, which currently lacks any FDA-approved oral therapies.
What’s next for Belite Bio and Tinlarebant?
Belite Bio will continue to advance Tinlarebant through clinical trials and anticipates sharing interim results that could significantly influence the treatment landscape for geographic atrophy.
